Abstract
Purpose: NSAIDs are commonly used for the treatment of pain and inflammation. The major side effects of chronic NSAID use are gastrointestinal (GI) symptoms and complications. Meloxicam is a recently FDA-approved NSAID with an extensive track record in Europe that suggests that it is better tolerated than conventional NSAIDs. The objective of this study was to develop a decision model comparing meloxicam with: i) generic NSAID therapy and ii) therapy with either of two COX-2 specific NSAIDs available in the US in patients at high risk for developing a GI adverse event.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
